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Urea space and total body water measurements by stable iso-
topes in patients with acute renal failure.
Background. Knowledge of urea volume of distribution
(Vurea) in patients with acute renal failure (ARF) is critical in
order to prescribe and monitor appropriate dialytic treatment.
We have recently shown that in ARF patients, Vurea estimation
by urea kinetic modeling is significantly higher than total body
water (TBW) by anthropometric estimation. However, these es-
timates of Vurea and TBW have not been validated by isotopic
methods, considered as reference measurement standards.
Methods. In this study, we measured Vurea by [13C]urea and
TBW by deuterium oxide (D2O) in 21 patients with ARF (14
males, 7 females, age 62.0 ± 10.6 years old, 83% Caucasian, 17%
African American) at three different centers. These measure-
ments were compared to TBW estimates from anthropometric
and bioelectrical impedance (BIA) measurements.
Results. Our results show that Vurea by [13C]urea (51.0±11.7 L)
is significantly higher than TBW estimated by all other methods
(TBW by D2O: 38.3 ± 9.8 L, P < 0.001; TBW by BIA: 45.7 ±
15.7 L, P = 0.08; TBW by Watson formula: 38.3 ± 7.3 L, P <
0.001; TBW by Chertow formula: 39.3 ± 7.8 L, P = 0.002, all
versus Vurea). Despite significant overestimation of the absolute
value and considerable variation, Vurea significantly correlated
with TBW by BIA (r = 0.66, P < 0.01) and TBW by D2O (r =
0.5, P = 0.04). There was also significant correlation between
D2O and BIA determined TBW (r = 0.8, P < 0.001).
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Conclusion. In terms of useful guidelines to prescribe a
specific dose of dialysis in patients with ARF, conventional
estimates of TBW as surrogates for Vurea should be used with
caution. We propose that these conventional estimates of TBW
should be increased by approximately 20% (a factor of 1.2) to
avoid significant underdialysis.
Recent studies have suggested that the dose of renal
replacement therapy in patients with acute renal failure
(ARF) is an important determinant of outcome [1–4].
In order to guide the quantification of delivered dialysis
dose, most investigators to date have applied concepts
of Kt/Vurea using principles derived from patients with
end-stage renal disease (ESRD), although these formu-
las have not been specifically validated in patients with
ARF [5]. To guide the prescription of therapy from blood-
based urea kinetic modeling, it is important to have an
accurate measurement of the volume of distribution of
urea (Vurea). Accurate determination of Vurea is also im-
portant for comparing low-molecular-weight solute re-
moval in continuous versus intermittent forms of renal
replacement therapy.
Vurea is generally assumed to be equivalent to total
body water (TBW), because of urea’s low molecular
weight and polar nature. Nevertheless, our laboratory has
recently reported that in ARF patients Vurea estimated
from blood-based urea kinetics is significantly higher than
estimates of TBW by anthropometric measurements [6].
While that study suggested that Vurea and TBW may
be substantially different in ARF patients, that conclu-
sion was based on less precise, indirect measurement
of both compartments. More accurate measurements of
TBW and Vurea can be accomplished by other indirect
measures, namely isotope infusion methods using deu-
terium oxide (D2O) and [13C] labeled urea, respectively
[7]. While these techniques have been applied to patients
with ESRD [8], there are, to date, no studies in ARF
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patients that examine TBW and Vurea by these indirect
measures.
Patients with ARF are likely to display substantial de-
rangements in body composition due to the nature of the
disease. The aim of this study was to measure TBW and
Vurea using stable isotope infusion techniques in ARF pa-
tients, and to compare these measures with practical, but
indirect measures of TBW, including anthropometric for-
mulas and bioelectrical impedance analysis (BIA). Our
results indicate that Vurea determined by [13C]urea is sub-
stantially and significantly higher than TBW determined
by D2O, as well as TBW derived from other indirect
measurements.
METHODS
Patient characteristics
The study was performed at three different sites
(Vanderbilt University Medical Center-VUMC, Maine
Medical Center-MMC, and Cleveland Clinic Foundation-
CCF). A total of 21 patients (10 VUMC, 2 MMC, 9 CCF)
were recruited for study purposes during the period of
September 1997 through August 2000. Inclusion criteria
included the diagnosis of ARF by the following criteria:
(1) serum creatinine increase of ≥0.5 mg/dL from base-
line if baseline SCr ≤1.4 mg/dL; (2) serum creatinine in-
crease of ≥1.0 mg/dL from baseline if baseline SCr ≥1.5
up to 4.9 mg/dL; and (3) age between 18 and 70 years old.
Institutional review board approval was obtained at all
study sites and informed consent was obtained from all
patients or next of kin.
Study design
The study design was prospective. All physician orders,
including the initiation and the timing of hemodialysis
(HD) throughout the entire hospitalization (if the study
subject was dialyzed), were supervised by the attending
nephrologists directly caring for the patient. No change
in patient care, including the initiation of HD or the fre-
quency of dialysis per week, was done for study purposes.
At the time of the study, 19 patients were on intermittent
hemodialysis (IHD), and 2 patients were not on renal
replacement therapy. In subjects on IHD, the study was
performed on a dialysis day, approximately 60 minutes
prior to scheduled IHD procedure.
The study consisted of infusion of the isotopes followed
by serial blood sampling. Specifically, at time 0, a blood
sample was obtained as baseline measurement and the
isotopes were then infused via a central catheter over
1 minute. Once the infusion was completed, blood sam-
ples were obtained at 1, 2, 5, 10, 20, 30, and 45 minutes. We
chose a relatively short period of time for isotope equi-
libration in order to minimize confounding effects from
other medical procedures and to minimize confounding
from ongoing urea generation in this critically ill subject
population. Forty minutes after initiation of the infusion,
BIA measurement was obtained. Subjects who were on
IHD were initiated on their scheduled treatment a min-
imum of 60 minutes after the infusion of the isotopes.
Urea volume of distribution was obtained in 18 of the 21
patients.
Isotopes
The volume of distribution of urea was measured by
a bolus infusion of [13C]urea (99%+; Cambridge Isotope
Laboratories, Woburn, MA, USA). Deuterium oxide in-
fusion (99%+; Cambridge Isotope Laboratories) was
used to measure total body water. Extracellular water
(ECW) measurements were estimated using a bolus infu-
sion of sodium bromide (NaBr; 99%+; Aldrich Chemical
Company, Inc., Milwaukee, WI, USA). For each subject,
70 lmol/kg of [13C]urea, D2O at a dose of 1.5 mmol/kg
and NaBr at a dose of 30 mg/kg were mixed into a 50 mL
syringe under sterile conditions on the day of the study.
Syringes were weighed before and after infusion of the
mixture.
Analytical procedures and calculation
Blood samples were collected into Venoject tubes con-
taining 15 mg Na2EDTA (Terumo Medical Corp., Elkton,
MD, USA) and immediately placed on ice. The blood was
spun in a refrigerated (4◦C) desktop centrifuge (Beckman
Instruments, Fullerton, CA, USA) at 3000 rpm for 10 min-
utes to obtain the plasma, which was stored at −70◦C,
for later analysis. Analysis of D2O and [13C]urea were
performed by isotope ratio mass spectrometry. Analysis
of plasma bromide was performed by high-performance
liquid chromatography (HPLC) [9]. All three measure-
ments were performed by Metabolic Solutions (Nashua,
NH, USA). This laboratory has extensive experience
making these measurements. The measurements were
made under the supervision of one operator with con-
trols to maintain quality control and consistency between
sample analyses. All measurements were performed and
reported in duplicates.
The calculations of TBW using dilution of the tracer
D2O [10], of urea volume of distribution using dilution
of the tracer [13C]urea [11], and of ECW using sodium
bromide [9] were made using established equations [12],
which require the determination of a biological steady-
state period. The steady-state period was determined
using compartmental modeling techniques. The optimal
linear model for steady state was determined, and in-
clusive time points with the least linear variation based
on this compartmental analysis were used as time points
for the steady-state period. These analyses demonstrated
that time points 20 to 45 minutes presented a steady-
state period during which the slope did not change.
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Fig. 1. (A, B) Plasma enrichments after deuterium oxide and [13C]urea
infusion. The figures represent pooled data of all the included patients.
(C) Plasma bromide concentration after sodium bromide infusion. The
figure represents pooled data of all the included patients. APE, atomic
percentage excess.
For corrected bromide space, the bromide concentra-
tion was corrected by subtracting the initial from the fi-
nal bromide concentration, multiplying by 0.90 for the
distribution of bromide in the nonextracellular spaces,
multiplying by 0.95 for the Donnan equilibrium for uni-
valent ions, and multiplying by 0.94 for water content
in plasma. Figures 1A–C depict changes in plasma D2O,
[13C]urea, and bromide over the time course of the ex-
periment. As can be seen, a relatively steady-state con-
dition was obtained for all isotopes after 20 minutes.
Importantly, the time period for equilibration of isotopes
is shorter than other reports [13, 8, 12]. In order to account
for the short equilibration period, we performed statisti-
cal analysis to predict TBW and Vurea at 2 and 4 hours
after the bolus infusion. The results showed no substantial
change in the difference between the two measurements.
Bioelectrical impedance analysis
Bioelectrical impedance analysis was performed using
a handheld device (Quantum, BIA 101Q; RJL Systems,
Clifton Township, MI, USA) by a trained research nurse
at each of the three centers. All tests were done at 40 min-
utes following isotope infusion. In brief, subjects were
placed in a supine position with their arms at but not
touching their sides, and with their legs separated. Elec-
trodes were attached to their contralateral hand and foot,
and a high-frequency, alternating low-voltage current was
applied across the limbs, resulting in two readings: re-
sistance and reactance. These values were entered into
Cyprus1.2 software (RJL Systems), allowing the calcu-
lation of various body composition values [14].
Anthropometric estimates of total body water
Total body water was estimated using the Watson and
Chertow formulas as shown below (height in cm and
weight in kg).
Watson [15]:
Male: TBW = 2.447 − (0.09516 × age)
+ (0.1074 × height) + (0.3362 × weight)
Female : TBW = −2.097 + (0.1069 × height)
+ (0.2466 × weight)
Chertow [16]:
TBW = −(0.07493713 × age) − (1.01767992 × male)
+ (0.12703384 × height)
− (0.04012056 × weight)
+ (0.57894981 × diabetes)
− (0.00067247 × weight2)
− 0.03486146 × (age × male)
+ 0.11262857 × (male × weight)
+ 0.00104135 × (age × weight)
+ 0.00186104 × (height × weight)
Where male = 1 (female = 0), diabetes = 1 (no diabetes
= 0)
Statistical analysis
Differences between the study variables, for exam-
ple, volume of distribution of urea by [13C]urea and total
body water estimates by D2O, BIA, and anthropomet-
ric equations, were evaluated by paired t test. Bonferroni
correction was done to take account of the number of tests
performed in multiple hypothesis testing situations. The
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Table 1. Patient demographics
Age years 62.0 ± 10.6
Gender 14M (66%) 7F (34%)
Race 17 Caucasian (83%) 4 AA (17%)
Weight kg 81.7 ± 15.2
Etiologies of ARF
Sepsis, ATN 5
Postoperative ATN 2
Hypotension, ischemic ATN 3
Contrast induced ATN 1
Cardiac surgery, ATN 2
Multifactorial ATN 6
Seizure disorder, ATN 1
Bone marrow transplantation, ATN 1
Abbreviations are: ATN, acute tubular necrosis; M, male; F, female; AA,
African American; ARF, acute renal failure.
Table 2. Mean (±SD) percent differences between total body water
determinations and volume of distribution of urea by [13C]urea
Variation from Difference
L Vurea by [13C]urea range L
TBW by D2O 39.4 ± 10.5 23.1 ± 18.2% −4.4–36.7
TBW by BIA 46.4 ± 14.8 10.2 ± 22.1% −10.5–33.9
Watson 38.6 ± 6.8 22.2 ± 19.5% −4.5–35.9
Chertow 39.6 ± 7.4 19.8 ± 21.1% −6.7–37.7
All means are less than Vurea by [13C]urea.
percent differences between Vurea and TBW estimates
were determined. Pearson correlation test was used for
correlation analysis between measurements. Finally, the
data were analyzed according to Bland and Altman plots
to assess the agreement between total body water by D2O
and TBW by other methods, and TBW by D2O with vol-
ume of distribution of urea by [13C]urea [17]. All tests of
significance were two-sided, and differences were consid-
ered statistically significant when the P value was < 0.05.
All data was expressed as mean ± SD. SAS version 8.2
was used for all analyses (SAS Institute, Cary, NC, USA).
RESULTS
Patient demographics
Table 1 summarizes the demographic as well as other
clinical data for the study patients. Sixty-six percent of the
studied patients were male, and 83% were Caucasian.
The etiologies of acute renal failure are also shown in
Table 1. All patients in the study displayed clinical evi-
dence of edema and fluid overload.
Volume of distribution of urea
The determination of mean urea volume of distribu-
tion (Vurea) by [13C]urea for all subjects was 51.0 ± 11.7 L
(64.3 ± 16.1% of body weight). The percentage variances
between estimates of TBW and Vurea are demonstrated
in Table 2. TBW by D2O underestimated Vurea by 23.1 ±
18.2% (P < 0.001). The difference between [13C]urea
based Vurea and D2O based TBW was evident through-
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Fig. 2. Distribution of Vurea and total body water (TBW) by D2O ac-
cording to body weight.
0
10
20
30
40
50
60
70
TB
W
,
 
L
13C-urea BIA D2O Chertow Watson
Fig. 3. Total body water determinations and volume of distribution of
urea by [13C]urea. †P = 0.08 vs. Vurea; ∗P < 0.01 vs. Vurea; and ∧P < 0.05
vs. bioelectrical impedance (BIA).
out all ranges of body weight. Figure 2 depicts the aver-
age Vurea versus TBW by isotopic measurements grouped
into 3 weight ranges (<75 kg, 75–90 kg, >90 kg). Of note,
there was a tendency for a smaller difference between
Vurea versus TBW by D2O at larger body weights, al-
though this trend was not significant. Anthropometric
estimates of TBW also underestimated Vurea by similar
percentages (Watson by 22.2 ± 19.5%, P < 0.001, Cher-
tow by 19.8 ± 21.1%, P = 0.002). BIA estimation of TBW
provided the closest measurement to Vurea by [13C]urea di-
lution and the extent of underestimation (10.2 ± 22.1%)
was only marginally significant (P = 0.08).
Total body water measurements
Figure 3 compares Vurea by [13C]urea measurement with
the measurement of TBW by D2O, anthropometic mea-
sures, and by BIA. The mean TBW determined by D2O
was 38.3 ± 9.8 L (47.8 ± 10.8% of body weight). Anthro-
pometrically calculated TBW estimates were 38.3 ± 7.3 L
(50.1 ± 4.5% of body weight) by Watson formula and
39.3 ± 7.8 L (47.4 ± 7.0% of body weight) by Chertow
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Table 3. Pearson correlation coefficients (r) and P values of study
variables
Vurea D2O BIA Watson
D2O 0.50 — — —
0.04
BIA 0.66 0.80 — —
0.004 0.0001
Watson 0.26 0.61 0.72 —
0.30 0.005 0.001
Chertow 0.20 0.55 0.70 0.84
0.43 0.01 0.001 0.001
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Fig. 4. Correlation between Vurea and total body water (TBW) by D2O
(dashed line).
formula. The differences between TBW by D2O versus
Watson and Chertow formulas were not significant. Total
body water by BIA revealed significantly higher estimate
of volume compared to TBW by D2O (45.7 ± 15.7 L,
56.0 ± 15.2% body weight, P = 0.02 versus D2O).
Although there was close correlation between these
methods (see below), BIA-determined TBW was also
statistically significantly higher than anthropometrically
calculated TBW (P < 0.01 versus Watson, P < 0.05 versus
Chertow).
Correlation analysis
While there was significant quantitative difference in
volume determination by different methods, the correla-
tion analysis demonstrated relatively close associations.
Table 3 depicts Pearson correlations between study vari-
ables. There was a very good correlation between D2O
and BIA determined TBW (r = 0.8, P = 0.001). D2O de-
termined TBW also correlated with anthropometrically
calculated TBW (r = 0.6, P = 0.005, with Watson, r =
0.55, P = 0.01 with Chertow). Vurea by [13C]urea also cor-
related with TBW by BIA (r = 0.66, P = 0.01) and D2O
estimated TBW (r = 0.5, P = 0.05, Figure 4).
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Fig. 5. Bland-Altman analysis of agreement between D2O determined
total body water (TBW) and Vurea.
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Fig. 6. Bland-Altman analysis of agreement between Vurea and bio-
electrical impedance (BIA) determined total body water.
Bland-Altman analysis
Bland-Altman analysis of the agreement between urea
volume of distribution by [13C]urea and total body water
estimations by D2O and BIA are depicted in Figures 5
and 6. Bland-Altman analysis of the residual error in-
dicated that the average difference between Vurea and
TBW by D2O was 12.7 ± 10.9 L. The two standard devi-
ation units for this mean difference was between −9.1 L
and 34.5 L. The slope of this line was not statistically
significantly different from zero (0.2459; r2 = 0.0441),
demonstrating that the differences were similar at low
versus high body weights and that the methods are inter-
nally constant. Similar analysis between Vurea and TBW
by BIA showed an average difference of 5.3 ± 11.9 L with
two standard deviation units between −18.5 L and 29.1
L. The slope of this relationship was also not statistically
significant from zero (−0.345; r2 = 0.1328). Mean differ-
ence between Vurea and Watson formula was 10.2 ± 16.1 L
(95% CI −20.0 to 42.4 L; r2 = 0.495; Fig. 7). This suggests
that the Watson formula systematically underestimated
Vurea at higher body weights.
Extracellular water pool
We also measured extracellular water pool by NaBr
and BIA. The results showed that ECW measurement by
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Fig. 7. Bland-Altman analysis of agreement between Vurea and Watson
formula determined total body water.
NaBr was 31.7 ± 12.1 L (79.5 ± 14.7% of total body water
by D2O). ECW determined by BIA was lower than ECW
by NaBr (22.7 ± 7.0 L; 57.9 ± 14.4% of TBW, P < 0.05).
DISCUSSION
This is the first study using isotopic techniques to
determine total body water and Vurea in critically ill
patients with acute renal failure. The results indicate
that Vurea, as determined by [13C]urea, is a significantly
larger space than TBW determined by deuterium oxide,
bioelectrical impedance, or anthropometrically derived
TBW. These results are striking and challenge the previ-
ous understanding of the distribution of urea among body
compartments.
These conclusions support earlier studies by our group
using urea kinetic techniques in patients with acute renal
failure receiving renal replacement therapy [6]. Specif-
ically, we utilized blood-based urea kinetic calculations
to estimate Vurea using single-pool, double-pool, and
equilibrated urea kinetic formulations, and found that
estimated Vurea was significantly higher than TBW de-
termined by BIA or anthropometric formulae. The con-
sistency between our previous findings using indirect
approaches, and the current study utilizing reference
techniques for measurement of body compartments,
demonstrate the robustness of the finding that Vurea ex-
ceeds TBW in patients with acute renal failure.
Clinically, the most important and relevant aspect of
this finding is that Vurea, which is a key component of
the dialysis prescription for patients with acute renal fail-
ure, cannot be equated with anthropometric estimates of
TBW [5]. Increasingly, data confirm that the outcome for
patients with acute renal failure requiring renal replace-
ment therapy correlates with the intensity of delivered
therapy, whether it is being provided intermittently or
continuously [1–4].
In clinical practice, Kt/Vurea is frequently used to de-
fine dialysis dose, and the accuracy of the method used
to estimate Vurea influences the reliability of the Kt/Vurea
calculation. Traditionally, Vurea is estimated by assuming
equivalence with TBW [5]. To the extent that TBW under-
estimates Vurea, this will result in an overestimate of pre-
scribed dialysis dose. This may have a significant impact
both on the dialysis prescription and on subsequent clin-
ical outcome. The suggestion that Vurea in patients with
acute renal failure is frequently underestimated is consis-
tent with our earlier studies reporting unacceptably low
doses of both prescribed and delivered dialysis in patients
with acute renal failure; in these studies, Kt/Vurea deter-
mined from blood-based urea kinetics (whether single-
pool, double-pool, or equilibrated) resulted in a higher
dose of delivered therapy than when Kt/Vurea was deter-
mined by fractional direct dialysate quantification of urea
[18, 19].
There are several possible explanations for the discrep-
ancy in measurements between TBW and Vurea in criti-
cally ill patients with acute renal failure as observed in
this study. One possible explanation would be the lack
of complete equilibration for urea concentration across
all body spaces. Indeed, the regional blood flow model
formulated by Daugirdas and Schneditz may be specifi-
cally applicable in critically ill patients with acute renal
failure [20–22]. In this patient population, the likelihood
of augmented urea disequilibrium between perfused and
non-perfused body compartments is certainly higher than
in the setting of stable patients with ESRD and may have
affected [13C]urea distribution. Problems related to hemo-
dynamic instability, as well as capillary leak syndromes,
also contribute to increased compartmentalization of so-
lutes and likely also affect [13C]urea distribution. Leaky
epithelia may also preferentially transport urea into cells
compared to transport out of cells. It is also well known
that critically ill patients with acute renal failure are ex-
tremely hypercatabolic, and the resulting increased re-
gional intracellular urea generation may also contribute
to disequilibrium [23]. Finally, urea may have cellular “re-
ceptors” that would increase urea space, as seen with cer-
tain drugs such as digoxin.
An additional explanation is that critically ill patients
with acute renal failure are also likely to develop substan-
tial derangements in total body water content and distri-
bution. A central concept in the modern management of
critically ill patients with sepsis, trauma, and other con-
ditions predisposing to the development of acute renal
failure is vigorous volume resuscitation in an effort to
maintain adequate tissue perfusion and oxygen delivery.
In this setting, inflammatory mediators frequently lead to
endothelial dysfunction, with a subsequent loss of vascu-
lar wall integrity, resulting in a capillary leak syndrome.
The consequent massive transudation of fluid from in-
travascular to interstitial spaces occurs particularly when
volume resuscitation is being prescribed to maintain in-
travascular volume. Labeled urea may more readily enter
than egress these spaces. Using isotopic sodium bromide,
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the finding in this study that extracellular water consti-
tutes 80% of total body water in critically ill patients with
acute renal failure demonstrates how dramatically water
metabolism is disordered in this patient population.
Earlier studies have suggested that in critically ill pa-
tients, massive cellular dehydration may occur, resulting
in cell shrinkage and a decrease in intracellular water
[24]. Using both bioelectrical impedance analysis and ra-
dioisotope dilution studies, Finn et al have demonstrated
that intracellular water decreases by 15% to 20% in
critically ill patients with either blunt trauma or sepsis
[25]. Both a decrease in intracellular water content as
well as an iatrogenic expansion of the extracellular wa-
ter compartment by vigorous volume resuscitation are
likely contributors to a dramatically altered intracellular-
to-extracellular water relationship observed in this study,
in contrast to previous studies in healthy subjects using
stable isotopes (e.g., 20:80% in patients with acute renal
failure versus 50:50% in healthy subjects) [7, 26].
This study also compared the reliability of anthropo-
metrically determined measures of total body water to
the use of isotopic deuterium as the reference standard.
In dialysis populations, TBW has been most commonly
estimated using either 58% of total body weight, the
Watson or Chertow formulas, or BIA. The former method
does not take into consideration any changes in body fat
mass, whereas the Watson equations were derived from
pooled data from several trials in normal, healthy volun-
teers using deuterium, tritium, or antipyrine dilution as
the gold standard criterion for TBW [15]. Of note, pa-
tients who might have disturbances in total body water
content were excluded from the original Watson analysis.
The Chertow formula has the advantage of being derived
from patients with renal failure, albeit without acute ill-
ness [16]. Hence, the suitability of using these estimates
of TBW in the critically ill population with acute renal
failure has not been sufficiently validated.
In this study, TBW measured by deuterium refer-
ence standard was similar to anthropometrically de-
termined TBW (both Watson and Chertow), whereas
BIA-determined TBW was significantly higher. How-
ever, while there was a consistency between the Watson
and Chertow formula means for measured TBW, in
deuterium-derived TBW, the correlation between the
methodologies were weak. Furthermore, Bland-Altman
analysis demonstrated that the Watson formula system-
atically underestimated TBW in comparison to deu-
terium as body weight increased. Critically ill patients
with the highest body weight likely include those pa-
tients who have received the most aggressive fluid re-
suscitation, and have the largest derangements in total
body water metabolism. This suggests that the Watson
formula should not be utilized for estimation of TBW
in ARF patients who have received aggressive volume
resuscitation.
It is notable that estimation of TBW by BIA provided
a closer approximation of Vurea than other methods of
estimating TBW. There was also a better correlation of
estimated TBW by BIA with Vurea than estimates derived
from anthropometric formulas. However, it is important
to note that similar to anthropometrically derived formu-
las for estimating total body water, BIA estimates using
standard regression equations did not prove to be suffi-
ciently precise or accurate in estimating either Vurea or
TBW determined by isotope dilution techniques for clin-
ical purposes. These findings suggest that either new an-
thropometrically determined formulas estimating Vurea
and/or TBW will need to be derived and validated in the
critically ill acute renal failure population, or new regres-
sion equations will need to developed for BIA estimates
in this patient population. These derivations will need to
take into account the potential effects of gender, race,
and whether or not patients are receiving renal replace-
ment therapy on estimates of TBW and Vurea. These ap-
proaches, however, will require significantly larger sam-
ple sizes than are available in the present study. This is an
important subject for future clinical research in critically
ill patients with acute renal failure.
A potential limitation of this study is the relatively
short time period allotted for isotope equilibration
(45 minutes), which was shorter than what is usually re-
ported in the literature. We chose a shorter than standard
time because of the critically ill nature of the study popu-
lation, in order to minimize potential confounding effects
from other medical procedures and solutions being pro-
vided, and to reduce the potential for ongoing urea gen-
eration. It is possible that full equilibration, especially of
[13C]urea, would not take place during this time period, es-
pecially to poorly perfused tissues. However, it should be
noted that if this is the case, the difference between Vurea
and TBW would likely increase rather than decrease. Fur-
ther, our analysis to predict TBW and Vurea at 2 and 4
hours after the bolus infusion did not show any change
in the difference between the two measurements. This
is consistent with the earlier reports suggesting that in
chronic renal failure patients, urea equilibrates between
body compartments within the time period of the current
study [27]. Thus, the central finding of this study that Vurea
as determined by [13C]urea is a significantly larger space
than TBW determined by deuterium oxide, and that urea
and water are differentially compartmentalized, would
likely remain valid.
While the results presented in this study are intrigu-
ing, one should also consider certain limitations. First,
the results are limited to critically ill patients with ARF
who have significant derangements in body composition
and fluid homeostasis. These derangements have influ-
enced the somewhat surprising results involving dramatic
changes in the intra- versus extracellular water ratio.
On the other hand, a careful analysis of the published
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literature suggests that intracellular to extracellular wa-
ter ratio even in healthy subjects is less than what is con-
ventionally accepted [7, 26]. During disease states such as
critical illness, malnutrition, and renal failure, this ratio
changes further toward an increase in extracellular space,
a finding consistent with our results [28]. Finally, the ma-
jority of the subjects in this study are male. Because total
body water is gender-specific, caution should be exerted
when interpreting our data.
CONCLUSION
We have demonstrated using reference standards that
in critically ill patients with acute renal failure, Vurea de-
scribes a larger space than total body water, which may
result in an overestimate of delivered urea clearance if
TBW is used as a surrogate for Vurea. Furthermore, nei-
ther currently available anthropometric methods nor bio-
electrical impedance are able to accurately estimate TBW
Vurea in acute renal failure patients. New approaches to
estimating both Vurea and TBW in patients with acute
renal failure are needed.
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